CL2018003649A1 - Edición genética mejorada - Google Patents
Edición genética mejoradaInfo
- Publication number
- CL2018003649A1 CL2018003649A1 CL2018003649A CL2018003649A CL2018003649A1 CL 2018003649 A1 CL2018003649 A1 CL 2018003649A1 CL 2018003649 A CL2018003649 A CL 2018003649A CL 2018003649 A CL2018003649 A CL 2018003649A CL 2018003649 A1 CL2018003649 A1 CL 2018003649A1
- Authority
- CL
- Chile
- Prior art keywords
- genetic editing
- enhanced genetic
- editing
- enhanced
- recombinases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662350941P | 2016-06-16 | 2016-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018003649A1 true CL2018003649A1 (es) | 2019-07-05 |
Family
ID=65019181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018003649A CL2018003649A1 (es) | 2016-06-16 | 2018-12-17 | Edición genética mejorada |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11708588B2 (enExample) |
| EP (1) | EP3472329A1 (enExample) |
| JP (1) | JP2020511931A (enExample) |
| CN (1) | CN109790551A (enExample) |
| CA (1) | CA3028074A1 (enExample) |
| CL (1) | CL2018003649A1 (enExample) |
| WO (1) | WO2018229521A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3976783A1 (en) * | 2019-05-29 | 2022-04-06 | Monsanto Technology LLC | Directed genome engineering using enhanced targeted editing technologies |
| CN112979821B (zh) * | 2019-12-18 | 2022-02-08 | 华东师范大学 | 一种提高基因编辑效率的融合蛋白及其应用 |
| CN111518220A (zh) * | 2020-05-14 | 2020-08-11 | 重庆英茂盛业生物科技有限公司 | 一种融合蛋白及其设计方法 |
| CN111909961B (zh) * | 2020-08-21 | 2022-04-19 | 华侨大学 | 一种CRISPR/Cas介导的ATL细胞基因编辑载体及其应用 |
| WO2022095929A1 (en) * | 2020-11-06 | 2022-05-12 | The University Of Hong Kong | Transferable type i-f crispr-cas genome editing system |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| ATE141646T1 (de) | 1986-04-09 | 1996-09-15 | Genzyme Corp | Genetisch transformierte tiere, die ein gewünschtes protein in milch absondern |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US7868149B2 (en) | 1999-07-20 | 2011-01-11 | Monsanto Technology Llc | Plant genome sequence and uses thereof |
| US6603061B1 (en) | 1999-07-29 | 2003-08-05 | Monsanto Company | Agrobacterium-mediated plant transformation method |
| AU2002238376B2 (en) | 2001-01-10 | 2007-05-10 | Lonza Cologne Gmbh | Modular transfection systems based on nucleoprotein filaments |
| US20090100536A1 (en) | 2001-12-04 | 2009-04-16 | Monsanto Company | Transgenic plants with enhanced agronomic traits |
| US8889394B2 (en) | 2009-09-07 | 2014-11-18 | Empire Technology Development Llc | Multiple domain proteins |
| US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
| BR112013021785A8 (pt) * | 2011-02-25 | 2018-07-03 | Recombinetics Inc | animais geneticamente modificados e métodos para fazer os mesmos |
| EP3257952B1 (en) * | 2012-09-11 | 2020-02-12 | Life Technologies Corporation | Nucleic acid amplification |
| AP2015008495A0 (en) * | 2012-10-30 | 2015-05-31 | Ct For Aquaculture Technologies Inc | Control of sexual maturation in animals |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| JP6665088B2 (ja) | 2013-06-17 | 2020-03-13 | ザ・ブロード・インスティテュート・インコーポレイテッド | 配列操作のための最適化されたＣＲＩＳＰＲ−Ｃａｓ二重ニッカーゼ系、方法および組成物 |
| BR112016013547A2 (pt) | 2013-12-12 | 2017-10-03 | Broad Inst Inc | Composições e métodos de uso de sistemas crispr-cas em distúrbios de repetições de nucleotídeos |
| CN104946621A (zh) | 2014-03-28 | 2015-09-30 | 中国科学院上海生命科学研究院 | 基因敲入组合物及其使用方法和应用 |
| DK3180426T3 (da) * | 2014-08-17 | 2020-03-30 | Broad Inst Inc | Genomredigering ved anvendelse af cas9-nickaser |
| IL287561B2 (en) * | 2014-10-01 | 2024-03-01 | Massachusetts Gen Hospital | Methods for increasing efficiency of nuclease-induced homology-directed repair |
| WO2016073990A2 (en) * | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
| EP3274453B1 (en) | 2015-03-26 | 2021-01-27 | Editas Medicine, Inc. | Crispr/cas-mediated gene conversion |
| US9988637B2 (en) * | 2015-10-26 | 2018-06-05 | National Tsing Hua Univeristy | Cas9 plasmid, genome editing system and method of Escherichia coli |
-
2017
- 2017-06-16 CN CN201780050339.4A patent/CN109790551A/zh active Pending
- 2017-06-16 JP JP2018565824A patent/JP2020511931A/ja not_active Abandoned
- 2017-06-16 US US16/310,664 patent/US11708588B2/en active Active
- 2017-06-16 CA CA3028074A patent/CA3028074A1/en active Pending
- 2017-06-16 EP EP17758941.3A patent/EP3472329A1/en not_active Withdrawn
- 2017-06-16 WO PCT/IB2017/000967 patent/WO2018229521A1/en not_active Ceased
-
2018
- 2018-12-17 CL CL2018003649A patent/CL2018003649A1/es unknown
-
2023
- 2023-06-30 US US18/345,653 patent/US20230416788A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020511931A (ja) | 2020-04-23 |
| CN109790551A (zh) | 2019-05-21 |
| WO2018229521A1 (en) | 2018-12-20 |
| WO2018229521A8 (en) | 2019-02-28 |
| EP3472329A1 (en) | 2019-04-24 |
| US20220010336A1 (en) | 2022-01-13 |
| US20230416788A1 (en) | 2023-12-28 |
| US11708588B2 (en) | 2023-07-25 |
| CA3028074A1 (en) | 2018-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125385T1 (el) | Συστημα πολλαπλων φορεων και χρησεις αυτου | |
| CO2017011344A2 (es) | Producción de vectores adeno-asociados de gran tamaño | |
| MX2019009361A (es) | Composiciones y metodos para el tratamiento de hemoglobinopatias. | |
| MX382223B (es) | Regulacion de expresion genica mediada por nucleasa. | |
| MX2017009324A (es) | Erradicacion guiada por arn de herpes simple tipo i y otros herpesvirus relacionados. | |
| MX2025010535A (es) | Metodos, composiciones y componentes para edicion crispr-cas9 de tgfbr2 en celulas t para inmunoterapia | |
| MX2022009148A (es) | Composiciones y metodos para el tratamiento de hemoglobinopatias. | |
| BR112019003100A2 (pt) | regulação da expressão gênica usando nucleases manipuladas | |
| SA517390590B1 (ar) | Ix عامل معدل، وتركيبات وطرق واستخدامات لنقل الجين إلى الخلايا، والأعضاء والأنسجة | |
| CY1123119T1 (el) | Αντινοηματικο νουκλεϊκο οξυ | |
| MX2020011620A (es) | Ingenieria genomica de plantas utilizando sistemas crispr/cas. | |
| CO2017004290A2 (es) | Composiciones y métodos para el silenciamiento de la expresión génica del virus de la hepatitis b | |
| MX2017005958A (es) | Composiciones de acido ribonucleico de interferencia (arni) contra el virus de la hepatitis b (hbv) y metodos de uso de estas. | |
| WO2015112896A3 (en) | Methods and compositions for sequences guiding cas9 targeting | |
| BR112018002600A2 (pt) | células para imunoterapia modificadas para direcionamento ao antígeno cd38 e para inativação do gene cd38 | |
| BR112017012765A2 (pt) | ?métodos para editar uma sequência de nucleotídeos, célula e linhagem de e. coli e método para produzir uma célula de e. coli? | |
| EA201991431A1 (ru) | УСИЛЕННЫЙ ОПОСРЕДОВАННЫЙ ТРАНСПОЗОНАМИ СЕМЕЙСТВА hAT ПЕРЕНОС ГЕНОВ И АССОЦИИРОВАННЫЕ КОМПОЗИЦИИ, СИСТЕМЫ И СПОСОБЫ | |
| MX368723B (es) | Composiciones y metodos para inhibir la expresion del gen alas1. | |
| MX388294B (es) | Peptidos y nanoparticulas para suministro intracelular de moleculas editoras de genoma. | |
| PH12016502555A1 (en) | Methods of preparing substituted nucleotide analogs | |
| MX2018001055A (es) | Promotores para mejorar la expresion en poxvirus. | |
| AU2017250265A1 (en) | Methods for creating synthetic chromosomes having gene regulatory systems and uses thereof | |
| AR097486A1 (es) | Plantas de cítricos resistentes a huanglongbing de cítricos (ex enverdecimiento) producido por candidatus liberibacter asiaticus (las) y chancro bacteriano producido por xanthomonas axonopodis pv. citri (xac) | |
| WO2018229521A8 (en) | ENHANCED GENE EDITION | |
| MX2017014206A (es) | Introgresion de un rendimieno qtl en plantas de cucumis sativus. |